Germline Mutations in Components of the Ras Signaling Pathway in Noonan Syndrome and Related Disorders

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cell Cycle

• Publication date

  2006-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/cc.5.15.3128PMID 16921267
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Stops along the RAS pathway in human genetic disease

  2006cited by this paper
• Inherited predispositions and hyperactive Ras in myeloid leukemogenesis

  2006cited by this paper
• Germline KRAS mutations cause Noonan syndrome

  2006cited by this paper
• HRAS mutation analysis in Costello syndrome: Genotype and phenotype correlation

  2006cited by this paper
• Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype.

  2006cited by this paper
• Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies.

  2006cited by this paper
• Germline Mutations in Genes Within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome

  2006cited by this paper
• Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome

  2006cited by this paper
• Mutations in Costello Syndrome : Detection of Constitutional Activating Mutations in Codon 12 and 13 and Loss of Wild-Type Allele in Malignancy

  2005cited by this paper
• An Acylation Cycle Regulates Localization and Activity of Palmitoylated Ras Isoforms

  2005cited by this paper
• Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations.

  2005cited by this paper
• The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease.

  2005cited by this paper
• Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.

  2005cited by this paper
• Germline mutations in HRAS proto-oncogene cause Costello syndrome

  2005cited by this paper
• Diverse Biochemical Properties of Shp2 Mutants

  2005cited by this paper
• Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases

  2005cited by this paper
• NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome.

  2005cited by this paper
• Noonan syndrome and related disorders: genetics and pathogenesis.

  2005cited by this paper
• Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.

  2004cited by this paper
• Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.

  2004cited by this paper
• Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells.

  2004cited by this paper
• Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?

  2004cited by this paper
• Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.

  2004cited by this paper
• Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.

  2004cited by this paper
• Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.

  2004cited by this paper
• Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia

  2004cited by this paper
• Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.

  2004cited by this paper
• Genotype-phenotype correlations in Noonan syndrome.

  2004cited by this paper
• Mouse model of Noonan syndrome reveals cell type– and gene dosage–dependent effects of Ptpn11 mutation

  2004cited by this paper
• The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.

  2003cited by this paper
• Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia

  2003cited by this paper
• GTPase activating proteins: critical regulators of intracellular signaling.

  2002cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• The Guanine Nucleotide-Binding Switch in Three Dimensions

  2001cited by this paper
• Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome

  2001cited by this paper
• RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML)

  1999cited by this paper
• Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1.

  1998cited by this paper
• Occurrence of myeloproliferative disorder in patients with Noonan syndrome.

  1998cited by this paper
• Mutations of the NF1 gene in leukemias from children without evidence of neurofibromatosis, type 1.

  1997cited by this paper
• K-ras is an essential gene in the mouse with partial functional overlap with N-ras.

  1997cited by this paper
• Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)

  1997cited by this paper
• Chronic myelomonocytic leukemia in childhood. A retrospective analysis of 110 cases.

  1997cited by this paper
• Occurrence of myeloproliferative disorder in patients with Noonan syndrome.

  1997cited by this paper
• Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells

  1996cited by this paper
• Neurofibromatosis/Noonan phenotype: a variable feature of type 1 neurofibromatosis

  1996cited by this paper
• Nf1 deficiency causes Ras-Dediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia

  1996cited by this paper
• Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders.

  1994cited by this paper
• Mapping a gene for Noonan syndrome to the long arm of chromosome 12

  1994cited by this paper
• Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras.

  1994cited by this paper
• Effector domain mutations dissociate p21ras effector function and GTPase-activating protein interaction

  1993cited by this paper
• ras oncogenes in human cancer: a review.

  1989cited by this paper

• Impaired MC3T3-E1 osteoblast differentiation triggered by oncogenic HRAS is rescued by the farnesyltransferase inhibitor Tipifarnib

  2025cites this paper
• Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia

  2022cites this paper
• KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications

  2022cites this paper
• Increased osteoclastogenesis contributes to bone loss in the Costello syndrome Hras G12V mouse model

  2022cites this paper
• RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis

  2021cites this paper
• A Rare Case of Diffuse-type Tenosynovial Giant Cell Tumor in a Teenager With Noonan Syndrome.

  2021cites this paper
• Zebrafish Cancer Predisposition Models

  2021cites this paper
• The RRAS2 pathogenic variant p.Q72L produces severe Noonan syndrome with hydrocephalus: A case report

  2021cites this paper
• Investigation of RASSF4 gene in head and neck cancers

  2021cites this paper
• Donor KIR Gene Content and KIR-Ligand Matching and Outcomes of Pediatric Patients with JMML Following Unrelated Donor Transplant.

  2021cites this paper
• Current Treatment of Juvenile Myelomonocytic Leukemia

  2021cites this paper
• Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome.

  2020cites this paper
• Myelodysplastic/Myeloproliferative Neoplasms

  2020cites this paper
• Juvenile myelomonocytic leukemia: who's the driver at the wheel?

  2019cites this paper
• Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia.

  2019cites this paper
• Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia

  2018cites this paper
• Oncogene mutational analysis in Chinese gastrointestinal stromal tumor patients

  2018cites this paper
• Discovering Functional ERK Substrates Regulating Caenorhabditis elegans Germline Development.

  2017cites this paper
• H-Ras and K-Ras Oncoproteins Induce Different Tumor Spectra When Driven by the Same Regulatory Sequences.

  2017cites this paper
• Retinoic-acid-mediated HRas stabilization induces neuronal differentiation of neural stem cells during brain development

  2016cites this paper
• Myelodysplastic and myeloproliferative disorders of childhood.

  2016cites this paper
• Insights into K-Ras 4B regulation by post-translational lysine acetylation

  2016cites this paper
• Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma

  2015cites this paper
• From clinical suspect to molecular confirmation of noonan syndrome; contribution of “best practice” genetic counseling and new technical possibilities

  2015cites this paper
• The Role of Redox-dependent Reactions with Kras Cysteine 118 in Tumorigenesis

  2015cites this paper
• How I treat juvenile myelomonocytic leukemia.

  2015cites this paper
• Clinical, genetic and functional characterization of intellectual disability disorders

  2014cites this paper
• Mutant NRASQ61 shares signaling similarities across various cancer types – potential implications for future therapies

  2014cites this paper
• Analysis of giant cell tumour of bone cells for Noonan syndrome/cherubism-related mutations.

  2013cites this paper
• Diverging gain-of-function mechanisms of two novel KRAS mutations associated with Noonan and cardio-facio-cutaneous syndromes.

  2013cites this paper
• Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo

  2013cites this paper
• Myelodysplastic/myeloproliferative neoplasms.

  2011cites this paper
• Juvenile Myelomonocytic Leukemia

  2010cites this paper
• Systems Biology of the MAPK1,2 Network

  2010cites this paper
• Molecular mechanisms regulating embryonic cerebral cortex development.

  2010influential citation
• Molecular basis of juvenile myelomonocytic leukemia

  2010cites this paper
• Clinical characteristics and pathophysiologic features of growth restriction, insulin resistance and tumour development

  2009cites this paper
• Mulibrey nanism : Clinical characteristics and pathophysiologic features of growth restriction, insulin resistance and tumour development

  2009cites this paper
• Malignant Diseases in Noonan Syndrome and Related Disorders

  2009cites this paper
• Isoform-specific ras functions in development and cancer.

  2009cites this paper
• Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors

  2009cites this paper
• Analysis of Ellis van Creveld syndrome gene products: implications for cardiovascular development and disease.

  2009cites this paper
• Systems Biology of Human Immunity and Disease

  2009cites this paper
• Clinical and molecular aspects of RAS related disorders

  2008cites this paper
• Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia

  2008cites this paper
• New small-molecule inhibitors of mitogen-activated protein kinase kinase

  2008cites this paper
• Distal phalangeal creases--a distinctive dysmorphic feature in disorders of the RAS signalling pathway?

  2007cites this paper
• Costello syndrome and related disorders

  2007cites this paper
• Neurological complications of cardio‐facio‐cutaneous syndrome

  2007cites this paper
• SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome

  2007cites this paper
• Germline gain-of-function mutations in RAF1 cause Noonan syndrome

  2007cites this paper
• An unexpected new role of mutant Ras: perturbation of human embryonic development

  2007cites this paper
• Uniparental disomy at chromosome 11p15.5 followed by HRAS mutations in embryonal rhabdomyosarcoma: lessons from Costello syndrome.

  2007cites this paper
• What’s new in the neuro-cardio-facial-cutaneous syndromes?

  2007cites this paper
• Germline gain-of-function mutations in SOS1 cause Noonan syndrome

  2007cites this paper
• Oncotargets and Therapy Dovepress Oncogene Mutational Profile in Nasopharyngeal Carcinoma

  year unknowncites this paper